Core Viewpoint - Via Biotechnology (01873) experienced a nearly 7% increase in stock price following the release of its interim results, indicating positive market sentiment despite a decline in revenue [1] Financial Performance - The company reported revenue of 832 million RMB, a year-on-year decrease of 15.27% [1] - Shareholder profit stood at 122 million RMB, reflecting a year-on-year increase of 4.28% [1] - The gross profit margin improved to 40.8%, up 6.3 percentage points compared to the same period last year, attributed to optimization in business structure and enhanced operational efficiency in CRO services [1] Business Development - Via Biotechnology has been investing in AI drug development for the past five years, with AI-related orders now accounting for 12% of new contracts, showing a growth trend [1] - The company possesses self-developed algorithms and platform capabilities in its AIDD and CADD platforms, along with experience in developing various drug forms [1] - Via is transitioning from a phase focused on computational methods in drug development to a new phase driven by AI in drug design, aiming to change the paradigm of drug design [1]